Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in HRD Malignant Mesothelioma
NCT04515836Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Feb 2021
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in malignant mesothelioma, sponsored by University of Chicago. Started Feb 2021; status: recruiting.
02
Drugs
olaparib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT04515836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515836.